A Phase I Multi-Institutional Study of Systemic Sorafenib in Conjunction with Regional Melphalan for In-Transit Melanoma of the Extremity

This publication has 39 references indexed in Scilit:

• Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
  Nature, 2010
• Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
  New England Journal of Medicine, 2010
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
  Cell, 2010
• Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
  Clinical Cancer Research, 2009
• Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma
  Clinical Cancer Research, 2009
• Optimizing regional infusion treatment strategies for melanoma of the extremities
  Expert Review of Anticancer Therapy, 2009
• A Multi-Institutional Experience of Isolated Limb Infusion: Defining Response and Toxicity in the US
  Journal of the American College of Surgeons, 2009
• Isolated Limb Infusion for In-Transit Malignant Melanoma of the Extremity: A Well-Tolerated but Less Effective Alternative to Hyperthermic Isolated Limb Perfusion
  Annals of Surgical Oncology, 2008
• Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
  Clinical Cancer Research, 2007
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
  British Journal of Cancer, 2006